Low-dose pioglitazone increases serum high molecular weight adiponectin and improves glycemic control in Japanese patients with poorly controlled type 2 diabetes

被引：23

作者：

Aso, Yoshimasa ^{[1
]}

Hara, Kenji ^{[1
]}

Ozeki, Noriyuki ^{[2
]}

Yatsuka, Chikako ^{[2
]}

Nakano, Tomoki ^{[1
]}

Matsumoto, Sachiko ^{[1
]}

Suetsugu, Mariko ^{[1
]}

Nakamachi, Takafumi ^{[1
]}

Takebayashi, Kohzo ^{[1
]}

Haruki, Kohsuke ^{[2
]}

Inukai, Toshihiko ^{[1
]}

机构：

[1] Dokkyo Med Univ, Koshigaya Hosp, Dept Internal Med, Saitama 3438555, Japan

[2] Dokkyo Med Univ, Koshigaya Hosp, Clin Lab Med, Saitama 3438555, Japan

来源：

DIABETES RESEARCH AND CLINICAL PRACTICE | 2009年 / 85卷 / 02期

关键词：

Pioglitazone; Adiponectin; High molecular weight; Hematocrit; Peripheral edema; FLUID RETENTION; 7.5; MG/DAY; THIAZOLIDINEDIONES; ACRP30/ADIPONECTIN; ROSIGLITAZONE; MONOTHERAPY; SECRETION; METFORMIN; MELLITUS; WOMEN;

D O I：

10.1016/j.diabres.2009.05.015

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

We investigated the effects of low-dose pioglitazone (7.5 mg/day) on serum high molecular weight (HMW) adiponectin and fluid retention (estimated from hematocrit) in 14 male and 16 female patients with type 2 diabetes. All of them were being treated with sulfonylureas and had poor glycemic control. Patients were given 7.5 mg/day of pioglitazone and were followed for 12 weeks at monthly intervals. In all 30 patients, HbA1c was significantly decreased after 12 weeks of treatment with pioglitazone (8.2 +/- 0.7% vs. 7.4 +/- 0.8%, P < 0.0001). Serum HMW adiponectin increased markedly from 5.2 (2.4, 8.6) mu g/ml at baseline to 9.8 (4.1, 12.6) mu g/ml at the end of pioglitazone treatment (P < 0.0001). When the changes were evaluated separately for each sex, diabetic men showed no increase of body weight or BMI after treatment, while HbA1c decreased significantly, and did Hct. Serum HMW adiponectin increased significantly after treatment. In diabetic women, neither body weight nor BMI increased after treatment with pioglitazone, as was the case for the men. HbA1c decreased significantly, and did Hct. Serum HMW adiponectin increased significantly after treatment. in conclusion, low-dose pioglitazone therapy could significantly improved glycemic control and markedly increased serum HMW adiponectin in both male and female Japanese patients with type 2 diabetes. (C) 2009 Elsevier Ireland Ltd. All rights reserved.

引用

页码：147 / 152

页数：6

共 26 条

[1]

Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes - A 6-month randomized placebo-controlled dose-response study [J].

Aronoff, S ;

Rosenblatt, S ;

Braithwaite, S ;

Egan, JW ;

Mathisen, AL ;

Schneider, RL .

DIABETES CARE, 2000, 23 (11) :1605-1611

[2]

Comparison of the effects of pioglitazone and voglibose on circulating total and high-molecular-weight adiponectin, and on two fibrinolysis inhibitors, in patients with Type 2 diabetes [J].

Aso, Y. ;

Yamamoto, R. ;

Suetsugu, M. ;

Matsumoto, S. ;

Wakabayashi, S. ;

Matsutomo, R. ;

Takebayashi, K. ;

Inukai, T. .

DIABETIC MEDICINE, 2007, 24 (09) :962-968

[3]

Comparison of serum high-molecular weight (HMS adiponectin with total adiponectin concentrations in type 2 diabetic patients with coronary artery disease using a novel enzyme-linked immunosorbent assay to detect HMW adiponectin [J].

Aso, Yoshimasa ;

Yamamoto, Ruriko ;

Wakabayashi, Sadao ;

Uchida, Toshihiko ;

Takayanagi, Kan ;

Takebayashi, Kohzo ;

Okuno, Takehiko ;

Inoue, Teruo ;

Node, Koichi ;

Tobe, Takashi ;

Inukai, Toshihiko ;

Nakano, Yasuko .

DIABETES, 2006, 55 (07) :1954-1960

[4]

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial [J].

Dormandy, JA ;

Charbonnel, B ;

Eckland, DJA ;

Erdmann, E ;

Massi-Benedetti, M ;

Kmoules, IK ;

Skene, AM ;

Tan, MH ;

Lefébvre, PJ ;

Murray, GD ;

Standl, E ;

Wilcox, RG ;

Wlhelmsen, L ;

Betteridge, J ;

Birkeland, K ;

Golay, A ;

Heine, RJ ;

Korányi, L ;

Laakso, M ;

Mokán, M ;

Norkus, A ;

Pirags, V ;

Podar, T ;

Scheen, A ;

Scherbaum, W ;

Schernthaner, G ;

Schmitz, O ;

Skrha, J ;

Smith, U ;

Taton, J .

LANCET, 2005, 366 (9493) :1279-1289

[5]

A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia [J].

Goldberg, RB ;

Kendall, DM ;

Deeg, MA ;

Buse, JB ;

Zagar, AJ ;

Pinaire, JA ;

Tan, MH ;

Khan, MA ;

Perez, AT ;

Jacober, SJ .

DIABETES CARE, 2005, 28 (07) :1547-1554

[6]

Thiazolidinediones expand body fluid volume through PPARγ stimulation of ENaC-mediated renal salt absorption [J].

Guan, YF ;

Hao, CM ;

Cha, DR ;

Rao, R ;

Lu, WD ;

Kohan, DE ;

Magnuson, MA ;

Redha, R ;

Zhang, YH ;

Breyer, MD .

NATURE MEDICINE, 2005, 11 (08) :861-866

[7]

Hiroshima K, 2002, FUEL CELLS, V2, P31, DOI 10.1002/1615-6854(20020815)2:1<31::AID-FUCE31>3.0.CO

[8]

2-Q

[9]

PPARγ activation enhances cell surface ENaCα via up-regulation of SGK1 in human collecting duct cells [J].

Hong, GZ ;

Lockhart, A ;

Davis, B ;

Rahmoune, H ;

Baker, S ;

Ye, L ;

Thompson, P ;

Shou, YP ;

O'Shaughnessy, K ;

Ronco, P ;

Brown, J .

FASEB JOURNAL, 2003, 17 (11) :1966-+

[10]

Pioglitazone (7.5 mg/day) added to flutamide-metformin in women with androgen excess:: additional increments of visfatin and high molecular weight adiponectin [J].

Ibanez, Lourdes ;

Lopez-Bermejo, Abel ;

Diaz, Marta ;

Enriquez, Goya ;

Valls, Carme ;

de Zegher, Francis .

CLINICAL ENDOCRINOLOGY, 2008, 68 (02) :317-320

← 1 2 3 →